Drugs

Apr 10, 2025, 15:20

Akhil Santhosh: Final Analysis of the ALCYONE Phase 3 Trial published in the Lancet Oncology

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X about recent paper Maria-Victoria Mateos and colleagues authored:

“Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial – The Lancet Oncology.”

Authors: Maria-Victoria Mateos, Meletios A Dimopoulos et al.

Akhil Santhosh

Andre Crepaldi Andrzej Jakubowiak Anna Marina Liberati cancer Chantal Doyen Eva G. Katz Fredrik Borgsten Genadi Iosava Jesús San-Miguel Kasey Bolyard Kenshi Suzuki Luděk Pour Mai Ngo Mamta Garg Maria Krevvata Maria-Victoria Mateos Meletios A. Dimopoulos Michele Cavo OncoDaily Oncology Paulo Lucio Philip Campbell Robin Carson Sebastian Grosicki Stefan Knop Sung-Soo Yoon Tomoaki Fujisaki Zsolt Nagy

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial

John Cena Announces He Overcame Skin Cancer Twice, Advocates for Sun Safety

William N. Hait to Receive 2025 AACR-Margaret Foti Award for Leadership in Cancer Research